Physician profile
Diane Kim
NPI 1952066706
$4,680.95
in general payments reported to CMS, 2019-2025
19 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $753 · 2023: $1,355 · 2024: $1,075 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,927.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,284.15 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $995.91 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $530.50 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $336.99 | 2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $333.89 | 2023-2025 | |
| Optinose US, INC. | $244.92 | 2023 | |
| Amgen INC. | $125.00 | 2022 | |
| Incyte Corporation | $124.98 | 2023 | Opzelura |
| Merck Sharp & Dohme LLC | $124.88 | 2024 | Lynparza |
| Ardelyx, INC. | $123.23 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $111.26 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.92 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $74.34 | 2025 | Voquezna |
| Phadia US INC. | $58.62 | 2023 | Immunocap |
| Ipsen Biopharmaceuticals, INC | $32.17 | 2025 | Iqirvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.09 | 2025 | |
| Gilead Sciences, INC. | $23.57 | 2025 | Epclusa |
| Solventum Corporation | $21.26 | 2025 | V.A.C. Veraflo |
| Abbvie INC. | $14.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.